NO973243L - Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical preparation for the treatment or prophylaxis of gynecological diseases - Google Patents

Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical preparation for the treatment or prophylaxis of gynecological diseases

Info

Publication number
NO973243L
NO973243L NO973243A NO973243A NO973243L NO 973243 L NO973243 L NO 973243L NO 973243 A NO973243 A NO 973243A NO 973243 A NO973243 A NO 973243A NO 973243 L NO973243 L NO 973243L
Authority
NO
Norway
Prior art keywords
preparation
prophylaxis
treatment
gynecological diseases
diphenylchromanes
Prior art date
Application number
NO973243A
Other languages
Norwegian (no)
Other versions
NO973243D0 (en
Inventor
Martin William Edwards
James Robertson Piggott
Virender Mohan Labroo
Ved Prakash Kamboj
Suprabhat Ray
Niels Korsgaard
Michael Shalmi
Birgitte Hjort Guldhammer
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO973243D0 publication Critical patent/NO973243D0/en
Publication of NO973243L publication Critical patent/NO973243L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse til- veiebringer nye anvendelser av forbin- delser med den generelle formel (I) (D behandling eller profylakse av gyne- kologiske sykdoimner, inkludert endo- metriose, dysfunltsjonelle blødninger, endometriumkreft, polycystisk ovarie- syndrom og anovulatorisk blødning, og dessuten til uttynning av endometriet. hvor r\ r* og R' uavhengig av hverandre er hydrogen, hydroksy, halogen, tri- fluormetyl, lavere alkyl, lavere alk- oksy eller (tertiært amino)(lavere alk- oksy), og R^ og R^ uavhengig av hver- andre er hydrogen eller lavere alkyl, eller som et farmasøytisk akseptabelt salt derav, i kombinasjon med en farma- søytisk akseptabel bærer, til fremstil- ling av et farmasøytisk preparat for behandling eller profylakse av gynekologiske sykdommer, inkludert endometriose, dysfunksjonelle blødninger, endrometriumkreft, poycystiske overiesyndrom og anovulatorisk blødning, og dessuten til uttynning av endometriet.The present invention provides novel applications of compounds of the general formula (I) (D treatment or prophylaxis of gynecological diseases, including endometriosis, dysfunctional bleeding, endometrial cancer, polycystic ovarian syndrome and anovulatory bleeding, and furthermore thinning of the endometrium, where R 1 and R 1 are independently hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino) (lower alkoxy), and R 2 and R independently of each other is hydrogen or lower alkyl, or as a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, for the preparation of a pharmaceutical preparation for the treatment or prophylaxis of gynecological diseases, including endometriosis, dysfunctional haemorrhage, endometrial cancer, poycystic upper syndrome and anovulatory haemorrhage, and also to thinning of the endometrium.

NO973243A 1995-01-13 1997-07-11 Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical preparation for the treatment or prophylaxis of gynecological diseases NO973243L (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
DK4795 1995-01-13
DK4495 1995-01-13
DK4695 1995-01-13
DK4895 1995-01-13
DK4595 1995-01-13
DK77195 1995-06-30
DK77295 1995-06-30
DK77095 1995-06-30
DK76995 1995-06-30
DK76895 1995-06-30
PCT/DK1996/000015 WO1996021444A1 (en) 1995-01-13 1996-01-10 Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of gynaecological disorders

Publications (2)

Publication Number Publication Date
NO973243D0 NO973243D0 (en) 1997-07-11
NO973243L true NO973243L (en) 1997-07-11

Family

ID=27579214

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973243A NO973243L (en) 1995-01-13 1997-07-11 Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical preparation for the treatment or prophylaxis of gynecological diseases

Country Status (11)

Country Link
EP (1) EP0804190A1 (en)
JP (1) JPH10511962A (en)
CN (1) CN1168096A (en)
AU (1) AU693628B2 (en)
CA (1) CA2208861A1 (en)
CZ (1) CZ212297A3 (en)
HU (1) HUP9702244A3 (en)
IL (1) IL116746A0 (en)
MX (1) MX9705219A (en)
NO (1) NO973243L (en)
WO (1) WO1996021444A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994390A (en) * 1996-10-28 1999-11-30 Novo Nordisk Trans-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US6043269A (en) * 1996-10-28 2000-03-28 Novo Nordisk A/S cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
IL129622A0 (en) * 1996-10-28 2000-02-29 Novo Nordisk As Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
AU4772397A (en) * 1996-10-28 1998-05-22 Novo Nordisk A/S Novel (cis)-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
CA2269936A1 (en) * 1996-10-28 1998-05-07 Lise Brown Christiansen Novel trans-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US5919817A (en) * 1996-10-28 1999-07-06 Novo Nordisk A/S Cis-3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
IL129626A0 (en) * 1996-10-28 2000-02-29 Novo Nordisk As Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US5985306A (en) * 1996-10-28 1999-11-16 Novo Nordisk A/S (+)-enantiomers of cis-3,4-chroman derivatives useful in prevention or treatment of estrogen diseases or syndromes
US6316494B1 (en) 1996-10-28 2001-11-13 Novo Nordisk A/S cis3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US5958967A (en) * 1996-10-28 1999-09-28 Novo Nordisk A/S Cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
IL129618A0 (en) * 1996-10-28 2000-02-29 Novo Nordisk As Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
CA2270055A1 (en) * 1996-10-28 1998-05-07 Novo Nordisk A/S Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
CA2270111A1 (en) * 1996-10-28 1998-05-07 Lise Brown Christiansen Novel (-)-enantiomers of cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
ZA979644B (en) * 1996-10-28 1998-04-28 Novo Nordisk As Heterocyclic compounds, compositions and uses.
AU4772097A (en) * 1996-10-28 1998-05-22 Novo Nordisk A/S Novel (cis)-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US7214706B2 (en) 2000-03-01 2007-05-08 Akzo Nobel N.V. Chroman derivatives as estrogenic compounds
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
CN101056868B (en) 2004-09-21 2012-05-02 马休爱德华兹股份有限公司 Substituted chroman derivatives, medicaments and use in therapy
JP6013349B2 (en) 2010-11-01 2016-10-25 メイ ファーマ, インク.Mei Pharma, Inc. Isoflavonoid compounds and methods for the treatment of cancer
EP2953938B1 (en) 2014-02-07 2017-08-02 Novogen Ltd. Functionalised benzopyran compounds and use thereof
HUE054998T2 (en) 2015-02-02 2021-10-28 Mei Pharma Inc Combination therapies for use in the treatment of breast cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease

Also Published As

Publication number Publication date
CN1168096A (en) 1997-12-17
HUP9877967A2 (en) 1998-12-28
EP0804190A1 (en) 1997-11-05
HUP9702244A3 (en) 1999-12-28
CZ212297A3 (en) 1997-11-12
MX9705219A (en) 1997-10-31
NO973243D0 (en) 1997-07-11
JPH10511962A (en) 1998-11-17
WO1996021444A1 (en) 1996-07-18
CA2208861A1 (en) 1996-07-18
AU4329396A (en) 1996-07-31
IL116746A0 (en) 1996-05-14
AU693628B2 (en) 1998-07-02

Similar Documents

Publication Publication Date Title
NO973243L (en) Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical preparation for the treatment or prophylaxis of gynecological diseases
AU683442B2 (en) Aminoacid derivates, medicaments containing these compounds and process for preparing the same
NO955047L (en) Secondary amines such as antidiabetic and anti-obesity agents
MY133647A (en) Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates
NO20015226L (en) Tri-aryl acid derivatives such as PPAR receptor ligands, pharmaceutical composition comprising the same and use of the same for the preparation of drug.
NO20074657L (en) Nitrogen-containing aromatic ring compounds
SE9902987D0 (en) Novel compounds
BRPI0409136A (en) pentacyclic heteroaromatic compound and medicinal use thereof
DE60204452D1 (en) [1,5] pyridine derivatives
BR0214164A (en) Cannabinoid receptor ligands
MXPA04002583A (en) Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity.
NO20023933D0 (en) New connections
BR0007589A (en) Cell proliferation inhibitors
DK0696281T3 (en) New 5-pyrrolyl-2-pyridylmethylsulfinylbenzimidazole derivatives
NO971625L (en) Novel peptides with immunomodulatory effects
DE60209362D1 (en) 3-SUBSTITUTED CHINOLIN-4-CARBOXYLIC ACID AMID DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS
NO983178L (en) Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
DK0937060T3 (en) New cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen-related diseases or syndromes
NO973340L (en) Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical composition for the treatment or prophylaxis of obesity
NO973342L (en) Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical composition for the treatment or prophylaxis of cerebral degenerative diseases
BG105923A (en) Novel morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives
NO973242L (en) Use of 3,4-diphenylchromanes for the preparation of a pharmaceutical composition for the treatment or prophylaxis of idiopathic or physiological gynecomastia
DK0937057T3 (en) New (-) - Enantiomers of cis-3,4-chromane derivatives useful in the prevention or treatment of estrogen-related diseases or syndromes
ATE293635T1 (en) STREPTOGRAMINE DERIVATIVES, THEIR PRODUCTION AND PREPARATIONS CONTAINING THEM
AP9801235A0 (en) Erythromycin derivatives.